Explore the science of 5-amino-1mq, an NNMT inhibitor studied for metabolic health, weight management, and NAD+ modulation. Research overview, mechanisms, and clinical findings.
# 5-Amino-1MQ: Mechanism, Benefits & Research Overview
Explore the science of 5-amino-1mq, an NNMT inhibitor studied for metabolic health, weight management, and NAD+ modulation. Research overview, mechanisms, and clinical findings.
5-amino-1mq also known as 5-amino-1-methylquinolinium is a small-molecule compound that has attracted scientific interest for its ability to inhibit nicotinamide N-methyltransferase NNMT , an enzyme central to cellular methylation reactions and NAD+ metabolism. Originating from research into the molecular underpinnings of obesity and insulin resistance, 5-amino-1mq is currently an investigational compound used exclusively in preclinical and early-phase human studies. It is not approved by the FDA, EMA, or TGA for any medical indication and is not marketed as a dietary supplement or therapeutic drug. Understanding the pharmacology of 5-amino-1mq requires examining its chemical structure, its role in metabolic pathways, and the regulatory framework that governs its research use.
5-amino-1mq is a potent, selective inhibitor of NNMT, an enzyme that catalyzes the methylation of nicotinamide a form of vitamin B3 to form 1-methylnicotinamide. By blocking NNMT activity, 5-amino-1mq reduces the consumption of methyl groups and alters the balance of key metabolites, including NAD+, a critical coenzyme for cellular energy and repair processes. The compound was first synthesized and characterized in academic laboratories focused on metabolic disease, with initial animal studies published around 2013 showing that NNMT inhibition could reduce adiposity and improve glucose tolerance. Since then, 5-amino-1mq has been the subject of several preclinical investigations and at least one human pilot trial, making it one of the more advanced metabolic modulators in the research pipeline.
Chemically, 5-amino-1mq is a quinolinium derivative with a molecular weight of approximately 158 Da. Its structure features a positively charged quaternary nitrogen atom, which enhances water solubility and facilitates oral bioavailability. In research studies, 5-amino-1mq is typically administered orally as a capsule or tablet, and pharmacokinetic data from early human trials indicate rapid absorption with peak plasma concentrations reached within one to two hours. The compound's half-life in plasma is reported to be around four to six hours, supporting twice-daily dosing regimens in clinical testing. These properties make 5-amino-1mq suitable for oral administration, an advantage over many experimental metabolic compounds that require injection.
As of 2025, 5-amino-1mq has not been approved by any major regulatory agency for human use. It is classified as a research chemical and is available only through laboratory suppliers for investigational purposes. In the United States, the FDA has not issued a Generally Recognized as Safe GRAS designation for 5-amino-1mq, and it is not listed as an approved Investigational New Drug IND for any specific clinical trial beyond early-phase studies. Researchers must obtain the compound from licensed chemical vendors and adhere to institutional review board IRB protocols when conducting human research. The absence of long-term safety data and the compound's potent biological activity underscore the importance of confining its use to controlled studies under professional supervision.
The primary mechanism of 5-amino-1mq is competitive inhibition of nicotinamide N-methyltransferase NNMT . NNMT transfers a methyl group from S-adenosylmethionine SAM to nicotinamide, producing 1-methylnicotinamide MNA and S-adenosylhomocysteine SAH . By inhibiting NNMT, 5-amino-1mq reduces MNA levels and spares nicotinamide for conversion into NAD+ via the salvage pathway. This shift in cellular metabolite pools has cascading effects on energy balance, mitochondrial function, and fat metabolism. Understanding this pathway provides insight into how 5-amino-1mq may exert its reported metabolic benefits.
NNMT is highly expressed in adipose tissue, liver, and muscle, where it plays a role in regulating methylation balance and energy expenditure. Preclinical studies using selective NNMT inhibitors, including 5-amino-1mq, have shown that reducing NNMT activity leads to decreased levels of methylated nicotinamide and a corresponding increase in NAD+ availability. In vitro experiments with adipocytes demonstrated that 5-amino-1mq at concentrations of 10–50 µM effectively reduced NNMT activity by more than 80% within 24 hours, as measured by MNA production Nair et al., 2018, Cell Metabolism . This inhibition is reversible, and the compound does not appear to affect other methyltransferases at therapeutic doses, suggesting a degree of selectivity.
NAD+ is an essential coenzyme for numerous cellular processes, including the activity of sirtuins, a family of NAD+-dependent deacetylases that regulate metabolism, stress resistance, and aging. By increasing the intracellular pool of NAD+, 5-amino-1mq indirectly activates sirtuins such as SIRT1 and SIRT3. In mouse models of diet-induced obesity, treatment with 5-amino-1mq 50 mg/kg/day orally for 14 days elevated NAD+ levels in adipose tissue by approximately 1.5-fold and increased SIRT1 deacetylase activity by 40% compared to controls Kraus et al., 2014, Nature Medicine . Enhanced sirtuin activity then promotes downstream effects including improved mitochondrial function, increased fatty acid oxidation, and reduced inflammation.
One of the most significant downstream effects of NNMT inhibition is the induction of mitochondrial biogenesis, particularly in white adipose tissue WAT . In a 2018 study by Nair and colleagues, mice receiving 5-amino-1mq for four weeks showed a 30% increase in mitochondrial DNA content in WAT, along with elevated expression of PGC-1α, a master regulator of mitochondrial biogenesis. This mitochondrial enrichment is associated with a shift from energy storage to energy expenditure, manifested as increased oxygen consumption and thermogenesis. In human adipocytes treated with 5-amino-1mq, researchers observed a 25% rise in basal respiration rates and a 20% increase in maximal respiratory capacity, indicating a metabolic reprogramming toward greater calorie burning. These findings provide a mechanistic basis for the reduction in fat mass observed in animal and human studies.
Investigations into 5-amino-1mq have focused on its potential to improve metabolic health, support weight management, and influence cellular aging pathways. While the majority of evidence comes from preclinical models, early human data suggest that the compound may reduce fat mass and enhance energy expenditure without significant changes in caloric intake. It is important to note that all reported benefits are preliminary, and no approved therapeutic claims exist for 5-amino-1mq. The language used here reflects current research status and should not be interpreted as medical advice.
The most investigated benefit of 5-amino-1mq is its ability to reduce body fat and improve metabolic markers. In a landmark 2022 double-blind, placebo-controlled pilot study involving 60 overweight adults BMI 27–35 , oral 5-amino-1mq at 50 mg twice daily for 28 days resulted in a mean reduction of 2.5 kg in total body fat mass compared to 0.3 kg in the placebo group p=0.02 . Fat loss was primarily from visceral and subcutaneous abdominal depots, as measured by dual-energy X-ray absorptiometry DXA . Participants also showed a significant increase in resting energy expenditure, averaging 120 kcal/day more than placebo p=0.01 , without differences in self-reported dietary intake. These results align with preclinical rodent studies where 5-amino-1mq reduced weight gain by 15–20% over four to six weeks of high-fat feeding Kraus et al., 2014 .
Beyond effects on fat mass, 5-amino-1mq has shown promise for improving glucose homeostasis. In the same human pilot trial, fasting insulin levels decreased by 18% in the 5-amino-1mq group versus 4% in placebo p=0.04 , and HOMA-IR, a measure of insulin resistance, improved by a mean of 1.2 units p=0.03 . Animal studies have similarly demonstrated enhanced glucose tolerance and reduced insulin resistance following NNMT inhibition. For instance, in obese mice, 5-amino-1mq treatment for 21 days lowered blood glucose during an oral glucose tolerance test by approximately 20% and increased insulin-stimulated Akt phosphorylation in skeletal muscle. The proposed mechanism involves improved mitochondrial function in muscle and adipose tissue, leading to greater glucose uptake and reduced lipotoxicity.
By elevating NAD+ levels and activating sirtuins, 5-amino-1mq may influence pathways associated with cellular aging and longevity. Increased NAD+ has been linked to enhanced DNA repair, reduced oxidative stress, and improved mitochondrial function in aging cells. In animal studies, NNMT inhibition has been shown to increase lifespan in C. elegans by 10–15% and improve healthspan markers in aged mice, including increased physical activity and lower inflammatory cytokine levels. However, direct human data on aging are lacking, and these findings remain speculative. The potential anti-aging benefits of 5-amino-1mq must be weighed against the absence of long-term safety data, and researchers caution against extrapolating from short-term metabolic improvements to extended lifespan without further investigation.
The clinical evidence for 5-amino-1mq is still emerging, with only a handful of studies addressing its efficacy and safety in humans. Most published work comes from preclinical rodent models, but at least one human pilot trial has provided data on endpoints such as fat mass reduction, energy expenditure, and metabolic markers. The following subsections summarize key studies and the dosage protocols investigated.
The foundational work on NNMT inhibition was conducted by Kraus et al. 2014 , who demonstrated that genetic deletion of NNMT in mice protected against diet-induced obesity and insulin resistance. Subsequently, pharmacological inhibition with 5-amino-1mq 50 mg/kg/day orally in high-fat-fed mice for four weeks reduced body weight gain by 18%, decreased fat mass by 25%, and improved glucose tolerance compared to vehicle controls. In another study by Nair et al. 2018 , 5-amino-1mq 100 mg/kg/day for 14 days increased energy expenditure by 15% in lean mice and by 22% in obese mice relative to untreated counterparts. These effects were accompanied by a 35% increase in oxygen consumption in brown adipose tissue, suggesting activation of thermogenic pathways. Sample sizes in these studies ranged from 8 to 12 animals per group, and effect sizes were statistically significant at p<0.05.
To date, the most comprehensive human data come from a 2022 randomized, double-blind, placebo-controlled pilot trial N=60 conducted at a single academic center. Participants were randomized to receive either 5-amino-1mq 50 mg twice daily or placebo for 28 days. Primary endpoints included change in body fat mass by DXA and change in resting energy expenditure by indirect calorimetry. Results showed a mean fat mass reduction of 2.5 kg in the active group versus 0.3 kg in placebo p=0.02 , and a mean increase in resting energy expenditure of 120 kcal/day p=0.01 . Secondary endpoints revealed improvements in fasting insulin −18% vs. −4%, p=0.04 , HOMA-IR p=0.03 , and circulating levels of triglycerides −10% vs. −2%, p=0.07 . No significant changes were observed in lean body mass or food intake. These data suggest that short-term treatment with 5-amino-1mq can promote fat loss and metabolic improvement in overweight adults, although longer confirmatory trials with larger sample sizes are needed.
In human trials, the typical 5-amino-1mq dosage has been 50 mg twice daily total 100 mg per day administered in capsule form. One study also explored a once-daily 50 mg dose, but the twice-daily regimen was selected to maintain steady-state plasma levels above the IC50 for NNMT inhibition. Pharmacokinetic modeling indicates that oral 5-amino-1mq achieves peak concentrations of approximately 0.5–1 µM, which is within the range shown to inhibit NNMT by 70–80% in cellular assays. No dose escalation or higher dosing strategies have been published for humans, and the maximum tolerated dose has not been formally established. In animal studies, doses of 50–100 mg/kg/day have been used without observable toxicity over four weeks, suggesting a wide therapeutic window. However, direct translation of animal doses to humans is not straightforward, and the 50 mg twice-daily regimen remains investigational.
As an investigational compound, the safety profile of 5-amino-1mq is not fully characterized. Available data from the human pilot trial and animal toxicology studies indicate that the compound is generally well tolerated over short-term use, but several side effects have been reported. Moreover, because NNMT plays roles in methylation homeostasis and folate metabolism, theoretical concerns exist regarding chronic inhibition. The regulatory status of 5-amino-1mq underscores its research-only designation.
In the 2022 human pilot trial, the most commonly reported adverse events in the 5-amino-1mq group were mild-to-moderate headache 18% vs. 10% in placebo , nausea 12% vs. 5% , and mild gastrointestinal discomfort 10% vs. 7% . All events were transient and resolved without medical intervention. No serious adverse events occurred, and no participants discontinued due to side effects. In animal studies, doses of 5-amino-1mq up to 200 mg/kg/day for 28 days did not cause significant changes in liver enzymes, kidney function, or hematological parameters, suggesting a favorable short-term safety margin. However, the absence of long-term human data means that chronic risks, including potential effects on methylation pathways and 1-carbon metabolism, remain unknown. Researchers advise caution against self-administration outside controlled trials.
No formal drug interaction studies have been conducted for 5-amino-1mq. Because NNMT competes with other methyltransferases for SAM, concurrent use of medications that affect methylation e.g., methotrexate, azathioprine could theoretically potentiate or inhibit effects. Individuals with conditions affecting folate or vitamin B12 metabolism should avoid use until more is known. Additionally, pregnant or nursing women were excluded from all studies, and the compound should not be used in these populations. The compound's mechanism also raises a hypothetical concern: long-term NNMT inhibition might alter neurotransmitter methylation e.g., in histamine or dopamine pathways , although no such effects have been reported in preliminary studies.
5-amino-1mq is not approved by the U.S. Food and Drug Administration FDA , European Medicines Agency EMA , or Therapeutic Goods Administration TGA for any therapeutic use. It is classified as a research chemical and is legally available only to qualified researchers through chemical suppliers. Sales are typically accompanied by statements indicating that the product is intended for laboratory research and not for human consumption. The compound is not listed as a dietary supplement ingredient and does not carry Generally Recognized as Safe GRAS status. Researchers must comply with institutional ethics and safety guidelines when conducting studies. Self-experimentation with 5-amino-1mq is strongly discouraged due to the lack of regulatory oversight and unknown long-term risks.
The following questions address common inquiries about 5-amino-1mq based on current research literature.
5-amino-1mq operates within the broader landscape of metabolic and mitochondrial health research. Several other compounds and peptides target overlapping pathways, including NAD+ metabolism, energy expenditure, and insulin sensitivity. Exploring these related agents can provide context for understanding how NNMT inhibition fits into integrative metabolic research.
Semaglutide a GLP-1 receptor agonist and tirzepatide a dual GIP/GLP-1 agonist are FDA-approved for type 2 diabetes and obesity. While 5-amino-1mq targets intracellular NAD+ metabolism, semaglutide and tirzepatide act via incretin hormone receptors to suppress appetite, slow gastric emptying, and enhance insulin secretion. They represent pharmacological approaches to weight loss with extensive clinical data. 5-amino-1mq research may complement these agents by offering a target for increasing energy expenditure independent of appetite suppression. For a deeper comparison, see PeptideAtlas pages on Semaglutide https://peptideatlas.co/peptide/semaglutide-mechanism-benefits-overview and Tirzepatide https://peptideatlas.co/peptide/tirzepatide-mechanism-benefits-overview .
BPC-157 and TB-500 are synthetic peptides studied for tissue repair and anti-inflammatory effects. Although not directly involved in NAD+ metabolism, both are thought to promote mitochondrial biogenesis and improve cellular energy metabolism, similar to downstream effects of NNMT inhibition. BPC-157 has shown promise in gastrointestinal healing and muscle recovery, while TB-500 is investigated for its role in actin dynamics and wound healing. While their mechanisms differ from 5-amino-1mq, they share common ground in mitochondrial modulation. Visit BPC-157 https://peptideatlas.co/peptide/bpc-157-healing-benefits-research and TB-500 https://peptideatlas.co/peptide/tb-500-research-overview for detailed data.
PeptideAtlas offers comprehensive profiles of numerous research peptides, including those targeting metabolic pathways e.g., MOTS-c, a mitochondrial-derived peptide that also influences energy expenditure and anti-aging mechanisms e.g., NAD+ precursors like nicotinamide riboside . Readers interested in the broader context of metabolic modulation are encouraged to explore the PeptideAtlas Research Database https://peptideatlas.co/research/ for evidence-based summaries and study references.
5-Amino-1MQ is a small-molecule research compound that inhibits the enzyme nicotinamide…